Razoxane for Crohn's colitis and non-specific proctitis.
Oral razoxane 125 mg daily brought active Crohn's disease into remission when used alone and mainly on an out-patient basis in all nine patients studied. Remissions took several months to achieve, but no relapses have occurred on treatment and no surgery has been necessary in any of the patients. In the two patients with active non-specific proctitis, oral razoxane 125 mg daily rapidly controlled the condition. Apart from mild bone marrow toxicity in one patient, no other acute toxicity has occurred and no long-term side-effects have been observed.
Kingston
R D
RD
Department of Clinical Studies, Trafford General Hospital, Davyhulme, Manchester.
Hellman
K
K
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011349:Proctitis / Q000188:drug therapy*; D011929:Razoxane / Q000008:administration & dosage / Q000627:therapeutic use*
D011929:Razoxane